UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042609
Receipt number R000048618
Scientific Title A study on the safety of a low-protein diet for patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
Date of disclosure of the study information 2021/01/01
Last modified on 2021/07/19 14:27:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study on the safety of a low-protein diet for patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)

Acronym

A study on the safety of a low-protein diet for patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)

Scientific Title

A study on the safety of a low-protein diet for patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)

Scientific Title:Acronym

A study on the safety of a low-protein diet for patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)

Region

Japan


Condition

Condition

Patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the safety of a low-protein diet for patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Safety assessments including hypotrophic status (nutritional assessment SGA, blood albumin level, total lymphocyte count, free fatty acids) and sarcopenia (sarcopenia screening items).

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Low-protein diet for 2 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

Patients with liver damage (ALT 40 U/L or higher) due to nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
BMI 25 or higher
CAP value 248 db/m or higher at the first FibroScan

Key exclusion criteria

Sarcopenia (AWGS2019)
Liver cirrhosis, alcoholic liver damage, autoimmune hepatitis, primary cholangitis, viral hepatitis, Wilson disease, and other liver diseases
Severe heart failure, diabetes mellitus, hypertension, interstitial pneumonitis, renal failure, autoimmune diseases, and infections
Insulin or steroids use, under hemodialysis
Malignant diseases
Under other dietary intervention
Pregnancy
Others

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Manabu
Middle name
Last name Nagayama

Organization

Jichi Medical University

Division name

Department of Medicine, Division of Gastroenterology

Zip code

329-0498

Address

3311-1 Yakushiji, Shimotsuke, Tochigi

TEL

0285-58-7348

Email

nagayama@jichi.ac.jp


Public contact

Name of contact person

1st name Manabu
Middle name
Last name Nagayama

Organization

Jichi Medical University

Division name

Department of Medicine, Division of Gastroenterology

Zip code

329-0498

Address

3311-1 Yakushiji, Shimotsuke, Tochigi

TEL

0285-58-7348

Homepage URL


Email

nagayama@jichi.ac.jp


Sponsor or person

Institute

Jichi Medical University

Institute

Department

Personal name



Funding Source

Organization

Keio University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Keio University

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Jichi Medical University

Address

3311-1 Yakushiji, Shimotsuke, Tochigi

Tel

0285-58-8960

Email

rinri@jichi.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2020 Year 12 Month 01 Day

Date of IRB


Anticipated trial start date

2021 Year 02 Month 01 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 12 Month 01 Day

Last modified on

2021 Year 07 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048618


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name